News und Analysen

If you are looking to buy some dividend stocks right now, you'll want to get to know Realty Income (NYSE: O), PepsiCo (NASDAQ: PEP), and Medtronic (NYSE: MDT). All three are reliable dividend payers

Medical device specialist Medtronic (NYSE: MDT) has not been the best of investments over the past five years. The stock has significantly lagged the market over this period, thanks to weak business

UnitedHealth (NYSE: UNH) revised its annual targets, disappointing stock market investors.

*Stock prices used were the afternoon prices of July 28, 2025. The video was published on July 30, 2025.

The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable.

Three Motley Fool contributors believe they've found such unstoppable stocks with the

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025. The headline news: the company posted Non-GAAP

The S&P 500 (SNPINDEX: ^GSPC) is offering investors a tiny yield of just 1.2% today. If you think you are being starved of dividend income, well, that's because you are. But you can do much better

Stryker (NYSE:SYK), a leading global medical technology company, reported financial results on July 31, 2025. The company delivered several key beats: Net sales (GAAP) reached $6.0 billion, topping

CMS Energy (NYSE:CMS), a major Midwest utility company providing electricity and natural gas to Michigan, announced its second-quarter 2025 results on July 31, 2025. The company reported

Explore the exciting world of Viking Therapeutics (NASDAQ: VKTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Although mighty American pharmaceutical company Eli Lilly (NYSE: LLY) has a dizzying number of commercialized products, it's a recently approved medication that's attracted outsized attention

A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in

Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP

Cigna Group (NYSE:CI), a global health services company offering integrated medical, pharmacy, and specialty care solutions, released its second-quarter earnings on July 31, 2025. The company

Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable

Huntsman (NYSE:HUN), the global specialty chemicals company serving industries from construction to transportation, reported its financial results for the second quarter on July 31, 2025. The

Genesis Energy (NYSE:GEL), a midstream energy infrastructure company focused on pipeline and transportation services in the Gulf of America, reported its second quarter 2025 earnings on July 31

iRhythm Technologies (NASDAQ:IRTC), a medical device company specializing in cardiac monitoring technology, reported its Q2 FY2025 results on July 31, 2025. The highlight was record revenue (GAAP)

If you're looking to invest in dividend stocks, one of the most popular ways to do it is with the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD). The exchange-traded fund (ETF) has net assets of

Indivior (NASDAQ:INDV), a global pharmaceutical company known for its treatments for opioid use disorder (OUD), reported results on July 31, 2025. The main news was a sharp outperformance compared

Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of

DexCom (NASDAQ:DXCM) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes

Neurocrine Biosciences (NASDAQ:NBIX), a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report

Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most

Explore the exciting world of Illumina (NASDAQ: ILMN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

Shares of AbbVie (NYSE: ABBV) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was